Felbamate

Felbamate
Clinical data
Trade names	Felbatol
AHFS/Drugs.com	Monograph
MedlinePlus	a606011
Routes of; administration	By mouth (tablets, oral suspension)
ATC code	N03AX10 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	>90%
Metabolism	Hepatic
Elimination half-life	20–23 hours
Identifiers
	IUPAC name (3-carbamoyloxy-2-phenylpropyl) carbamate;
CAS Number	25451-15-4 ;
PubChem CID	3331;
IUPHAR/BPS	5473;
DrugBank	DB00949 ;
ChemSpider	3214 ;
UNII	X72RBB02N8;
KEGG	D00536 ;
ChEBI	CHEBI:4995 ;
ChEMBL	ChEMBL1094 ;
CompTox Dashboard (EPA)	DTXSID9023041 ;
ECHA InfoCard	100.042.714
Chemical and physical data
Formula	C11H14N2O4
Molar mass	238.243 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N)OCC(c1ccccc1)COC(N)=O;
	InChI InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15) ; Key:WKGXYQFOCVYPAC-UHFFFAOYSA-N ;
	(verify)

Felbamate (marketed under the brand name Felbatol by MedPointe) is an anticonvulsant used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox–Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory epilepsy.